Long-term response to etanercept monotherapy in moderate to severe psoriasis: Assessment in daily practice by the maintenance of low values of PASI and BSA

Journal of Dermatological Treatment

Volumn 25, Issue 1, 2014, Pages 54-56

  Fernández Torres, Rosa María ^a   Paradela, Sabela ^a   Fonseca, Eduardo ^a  

^a Oral and Maxillofacial Surgery Service University Hospital of La Coruña   (Spain)

Author keywords

BSA; Etanercept; Long term response.; PASI; Psoriasis

Indexed keywords

ETANERCEPT;

ADULT; ARTICLE; BODY SURFACE; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PSORIASIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890535833     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.755254     Document Type: Article

References (9)

1. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
2. Gottieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632.
3. Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, et al. A randomized open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598-603.
4. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishet al. Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
5. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164:1091-1096.
6. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143: 719-726.
7. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 year of treatment with etanercept. J Rheumatol. 2006;33:712-721.
8. Mazzotta A, Esposito M, Schipani C, Chimenti S. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study. J Dermatolog Treat. 2009;20:354-358.
9. Van Lümig Driessen RJ, Boezeman JB, van der Kerkhof PC, de Jong EM. Long-term efficacy of etanercept for psoriasis in daily practise. Br J Dermatol. 2012;166:440-469.